Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma

Journal of Clinical Oncology

Volumn 24, Issue 18, 2006, Pages 2879-2884

  Malogolowkin, Marcio H ^a   Katzenstein, Howard ^b   Krailo, Mark D ^b   Chen, Zhengjia ^b   Bowman, Laura ^b   Reynolds, Marleta ^b   Finegold, Milton ^b   Greffe, Brian ^b   Rowland, Jon ^b   Newman, Kurt ^b   Womer, Richard B ^b   London, Wendy B ^b   Castleberry, Robert P ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEPATOBLASTOMA; HUMAN; INFANT; MALE; MULTIPLE CYCLE TREATMENT; NEWBORN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME; ADOLESCENT; LIVER TUMOR; PRESCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEPATOBLASTOMA; HUMANS; INFANT; LIVER NEOPLASMS; MALE; VINCRISTINE;

EID: 33745553595     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.6013     Document Type: Article

References (23)

1. Ortega JA, Krailo MD, Haas JE, et al: Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: A report from the Children's Cancer Study Group. J Clin Oncol 9:2167-2176, 1991
2. Douglass EC, Reynolds M, Finegold M, et al: Cisplatin, vincristine, and flourouracil therapy for hepatoblastoma: A Pediatric Oncology Group Study. J Clin Oncol 11:96-99, 1993
3. Ortega JA, Douglass EC, Feusner JH, et al: Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 18:2665-2675, 2000
4. Cheung NV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058, 1991
5. Cushing B, Giller R, Cullen JW, et al: Randomized comparison of combination chemotherapy with etoposide bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: A pediatric intergroup study - Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 22:2691-2700, 2004
6. Katzenstein HM, London WB, Douglass EC, et al: Treatment of unresectable and metastatic hepatoblastoma: A Pediatric Oncology Group phase II study. J Clin Oncol 20:3438-3444, 2002
7. Ortega JA, Rios P, Malogolowkin, MH: Successful treatment of hepatoblastoma (HB) with an intensified platinum regimen. Proc Am Soc Clin Oncol 17:545a, 1998 (abstr 2091)
8. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
9. Borsi JD, Csaki C, Ferencz T, et al: Administration of ethyolyl (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Anticancer Drugs 7:121-126, 1996
10. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trial. Biometrics 35:549-556, 1979
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data. New York, NY, John Wiley and Sons, 1980
13. von Schweinitz D, Byrd DJ, Hecker H, et al: Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma: Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. European J Can 33:1243-1249, 1997
14. Sasaki F, Matsunaga T, Iwafuchi M, et al: Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor. J Ped Surg 37:851-856, 2002
15. Ninane J, Perilongo G, Stalen JP: Effectiveness and toxicity of cisplatin and doxorubicin (PLADO) in childhood hepatoblastoma and hepatocellular carcinoma: A SIOP pilot study. Med Ped Oncol 19:199-203, 1991
16. Fuchs J, Rydzynski J, Von Schweinitz D, et al: Pretreatment prognostic factors and treatment results in children with hepatoblastoma: A report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 95:172-182, 2002
17. Perilongo G, Shafford E, Maibach R, et al: Risk-adapted treatment for childhood hepatoblastoma: Final report of the second study of the International Society of Paediatric Oncology - SIOPEL 2. Eur J Cancer 40:411-421, 2004
18. Brown B: The randomized clinical trial. Stat Med 3:307-311, 1984
19. Chalmers CT: The randomized clinical trial as a basis for therapeutic decisions in, The Randomized Clinical Trial as a Basis for Therapeutic Decisions. New York, NY, Marcel Dekker, 1982
20. Pinsky CM: Experience with historical control studies in cancer immunotherapy. Stat Med 3:325-329, 1984
21. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/ Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
22. Dall'Igna P, Cecchetto G, Dominici C, et al: Carboplatin and doxorubicin (CARDOX) for nonmetastatic hepatoblastoma: A discouraging pilot study. Med Ped Oncol 36:332-334, 2001
23. Malogolowkin M, Katzenstein HM, Krailo M, et al: Outcome of patients with recurrent or progressive hepatoblastoma: A report of the intergroup liver tumor study INT-0098. Pediatr Blood Cancer 45:404, 2005 (abstr 083)